Obesogenic and Ketogenic Diets Distinctly Regulate the SARS-CoV-2 Entry Proteins ACE2 and TMPRSS2 and the Renin-Angiotensin System in Rat Lung and Heart Tissues비만 및 케톤 생성 식단은 쥐의 폐와 심장 조직에서 SARS-CoV-2 진입 단백질 ACE2 및 TMPRSS2와 레닌-안지오텐신 시스템을 뚜렷하게 조절합니다Article Published on 2021-09-252022-09-10 Journal: Nutrients [Category] SARS, 바이오마커, 유전자 메커니즘, [키워드] ACE2 Affect Alter angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anti-inflammatory effect attenuate components diet elevated enzyme Gene Expression heart hearts IL6 increase individuals Inflammation inflammatory gene inflammatory genes interleukin-6 interleukin-6 receptor ketogenic Ketogenic diet Ketogenic Diets ketones lung lung tissues Lungs MasR mechanism Migration obese obesity obesogenic outcomes protease Protein RAS RAT Renin renin-angiotensin system SARS-CoV-2 SARS-CoV-2 entry Serine serine 2 severity Severity of infection sucrose System tested the SARS-CoV-2 tissues TLR4 TMPRSS2 TMPRSS2 level TMPRSS2 levels TNF-alpha Toll-like receptor toll-like receptor 4 transmembrane transmembrane protease serine 2 Viral viral entry were measured [DOI] 10.3390/nu13103357 PMC 바로가기 [Article Type] Article
Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case seriesCase Report Published on 2021-09-182022-10-30 Journal: Journal of Medical Case Reports [Category] COVID-19, SARS, [키워드] acute respiratory syndrome Antibiotics antivirals approach Asian average biochemical parameter Blood C-reactive protein case sery caused Clinical course Clinical outcome clinically coronavirus coronavirus disease COVID-19 Critical illness Critically ill cytokine Cytokines Cytosorb CytoSorb therapy disease distress drugs hospital Hydroxychloroquine Immunopathogenesis inflammatory mediator intensive care intensive care unit (ICU) interleukin-6 receptor mean arterial pressure Novel coronavirus pandemic pathology Patient pharmacological reduce required respiratory complication responsible severely ill patient supplementary material survived syndrome the cytokine storm Tocilizumab treat treated Treatment [DOI] 10.1186/s13256-021-03021-y PMC 바로가기 [Article Type] Case Report
Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantationArticle Published on 2021-08-132022-10-04 Journal: Scientific Reports [Category] 신약개발, [키워드] Allograft association C-allele center DNA Donor female organ Genetic variant Genotype Groningen IL-6 receptor IL6 IL6R Immunogenetics Impact increased risk independent interleukin-6 interleukin-6 receptor Interleukins kidney male organ morbidity Netherland Observational cohort study Occurrence performed polymorphism Prognostic marker reduced risk rejection renal renal replacement therapy rs2228145 rs8192284 Single nucleotide polymorphism SNP SNPs university [DOI] 10.1038/s41598-021-95714-z PMC 바로가기 [Article Type] Article
Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome A single center experience from Pune, Western IndiaCOVID-19 관련 사이토카인 방출 증후군 관리를 위한 토실리주맙과 스테로이드의 병용 요법 인도 서부 푸네의 단일 센터 경험4900 Published on 2021-07-232022-09-12 Journal: Medicine [Category] 진단, [키워드] Administered Admission Anti-inflammatory approved Bacterial bacterial and fungal infections blood stream Cardiac arrhythmia Clinical improvement co-morbidities co-morbidity combination therapy Complication conducted COVID-19 CRS Cytokine release syndrome Cytokine storm D-dimer death Dexamethasone effective Efficacy and safety Encephalopathy evaluate females fibrosis Fungal infection hospital Hospital acquired hypertension Hypotension ICU IL-6 incidence increased risk India Infectious complications inflammatory lung damage intensive care intensive care unit interleukin-6 interleukin-6 receptor lung damage Lung fibrosis management Mechanical mechanical ventilation morbidities Mortality not need outcome Patient patients patients with COVID-19 Pneumonia primary endpoint Randomized controlled trials receptor antagonist Relative risk required retrospective cohort study risk factor Safe secondary Secondary outcomes Seven severity significantly single center steroid Steroids syndrome TCZ therapy thought Tocilizumab Treatment Ventilation ventilator worsening [DOI] 10.1097/MD.0000000000026705 PMC 바로가기 [Article Type] 4900
Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndromeCOVID-19 사이토카인 폭풍 증후군의 가용성 인터루킨-6 수용체Article Published on 2021-05-182022-09-12 Journal: Cell Reports Medicine [Category] MERS, SARS, 진단, [키워드] blockade COVID-19 COVID-19 cytokine storm cytokine Cytokine storm elevated help IL-6 interleukin-6 interleukin-6 receptor patients reduce mortality severe COVID-19 sIL-6R syndrome threshold threshold concept Tocilizumab tocilizumab. treat [DOI] 10.1016/j.xcrm.2021.100269 PMC 바로가기 [Article Type] Article
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial중증 또는 치명적인 COVID-19로 병원에 입원한 환자의 Sarilumab: 무작위 배정, 이중 맹검, 위약 대조, 3상 시험Clinical Trial Published on 2021-05-012022-09-12 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단, [키워드] adverse event assessments assigned block Brazil Canada Care Clinical improvement Course COVID-19 COVID-19 severity Critical Critical disease death double-blind Efficacy EudraCT Face mask FIVE France Germany greater hazard ratio hospital immunomodulatory therapy inhibitor intensive care interleukin-6 receptor Intervention intravenous investigator Italy Japan Laboratory laboratory-confirmed SARS-CoV-2 infection mechanical ventilation median time modified intention-to-treat nasal nine no significant difference outcome outcome assessors oxygen supplementation Patient phase 3 trial Placebo placebo-controlled Pneumonia primary endpoint Proinflammatory cytokine proportion randomised Randomly receive receiving Regeneron Pharmaceuticals Registered remained required requiring supplemental oxygen Russia Safety Sanofi sarilumab screened secondary endpoint Seven Spain suggested supplemental oxygen Support survival the placebo group treatment-emergent adverse event Trial WHO with COVID-19 [DOI] 10.1016/S2213-2600(21)00099-0 PMC 바로가기 [Article Type] Clinical Trial
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19코비드-19에 걸린 중환자의 인터루킨-6 수용체 길항제Randomized Controlled Trial Published on 2021-04-222022-09-12 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단, [키워드] 24 hour Adaptive platform trial adjusted Adult patient Analysis antagonist antagonists assigned Bayesian control group coronavirus disease criteria Critically ill patient cumulative odds ratio Efficacy evaluated greater groups hazard ratio ICU ICUs Ill In-hospital death intensive care interleukin-6 receptor International interquartile range median multifactorial Odds ratio organ organ support outcomes Patient posterior probability Primary outcome Randomly receive receiving REMAP-CAP sarilumab secondary analysis standard care statistical model supported survival Tocilizumab Treatment Trial yielding [DOI] 10.1056/NEJMoa2100433 PMC 바로가기 [Article Type] Randomized Controlled Trial
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia중증 코로나19 폐렴으로 입원한 환자의 토실리주맙Clinical Trial Published on 2021-04-222022-09-12 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단, [키워드] 24 hour 95% CI 95% confidence interval Case report clinical status Cohort studies Coronavirus disease 2019 COVACTA COVID-19 pneumonia death Department discharge discharged dose elevated first dose Hoffmann-La Roche Hospitalization Hospitalized hospitalized patient Human hyperinflammation immune dysregulation interleukin-6 interleukin-6 receptor lower mortality median value modified intention-to-treat monoclonal antibody non-ICU occurred outcome participant Patient phase 3 trial Placebo Placebo-controlled trials Primary outcome randomization Randomized randomized trial randomly assigned patient receive retrospective safety population second dose Secondary analyses Serious Adverse Event significantly single intravenous infusion supplemental oxygen the patient the placebo group Tocilizumab [DOI] 10.1056/NEJMoa2028700 PMC 바로가기 [Article Type] Clinical Trial
Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6Molecular Biosciences Published on 2021-04-152022-10-31 Journal: Frontiers in Molecular Biosciences [Category] COVID-19, [키워드] administration analyzed antibody baseline baseline level Characteristics chest imaging clinical Clinical outcome Clinical prognosis Cohort compassionate use Compliance consecutive patient coronavirus – COVID-19 coronavirus disease COVID-19 critical condition Cytokine storm death group declined died early stage Efficacy elevated evaluate exclusion criteria IL-6 IMPROVE inclusion criteria interleukin-6 interleukin-6 receptor intravenously Laboratory tests lack lymphocyte Mild objective offered pathway Patient patients patients with COVID-19 PCT procalcitonin receiving Result SARS-CoV-2 TCZ the timing tocilizumab (TCZ) Treatment were used [DOI] 10.3389/fmolb.2021.651662 PMC 바로가기 [Article Type] Molecular Biosciences
What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak토실리주맙은 어떻습니까? COVID-19 발생 기간 동안 NYC 병원의 후향적 연구Randomized Controlled Trial Published on 2021-04-082022-08-13 Journal: PLoS ONE [Category] MERS, SARS, 임상, 진단, [키워드] 7-point ordinal scale 95% CI absence Admission Bacterial infection Bacterial infections bacterial superinfection bacterial superinfections baseline Control Corticosteroid Corticosteroids COVID-19 COVID-19 outbreak demographics Endpoint evaluated Evidence evidence of gastrointestinal perforation Health hospital Hypoxemia Illness severity incidence include increase in independent independent of inflammatory phase interleukin-6 interleukin-6 receptor large academic medical center measure Methylprednisolone New York City no evidence of no increase Ordinal Scale outcome Oxygenation Patient patients with COVID-19 primary endpoint primary endpoints Primary outcomes receiving receptor blocker Result Retrospective analysis Retrospective study secondary secondary bacterial infection Secondary bacterial infections Secondary endpoints severe disease Support t-test Tocilizumab ventilator ventilator free survival ventilator-free survival [DOI] 10.1371/journal.pone.0249349 PMC 바로가기 [Article Type] Randomized Controlled Trial